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Hypervariable region 1 (HVR1) of hepatitis C virus (HCV) is known to contain neutralizing epitopes. We previously found that
murine antibodies against HVR1-#6 captured a different isolate, HCV-#7, and cross-reacted with the HVR1 peptide of HCV-#7.
We investigated the inducibility and generality of cross-reaction of animal anti-HVR1 antibody responses in this study.
Anti-HVR1-#7 antibodies, which were induced in mice and a chimpanzee by immunization, were found to be cross-reactive
to HVR1-#6 peptide. Antibody responses against HVR1-#6-1 and HVR1-#7 peptides were detected in 11/165 (6.7%) and
26/165 (15.8%) HCV-infected individuals, respectively. Nine HVR1 sequences from six individuals, who were strongly positive
for anti-HVR1-#7 antibodies, were only 50–64.5% identical to that of HVR1-#7. All nine of these HVR1 peptides were reactive
to sera from the six patients and/or to antisera against HVR1-#6 and HVR1-#7 produced in mice and chimpanzees.
Cross-inhibition tests of chimpanzee antisera indicated that a given species of anti-HVR1 antibodies was reactive to multiple
HVR1 sequences. Fine epitope mapping of polyclonal and monoclonal anti-HVR1 antibodies showed that conserved
subregions in HVR1 sequences determined the observed immunological cross-reactivity. Our data demonstrate that
cross-reacting anti-HVR1 antibodies are inducible by a single peptide immunization. © 1999 Academic Press
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oINTRODUCTION
Hepatitis C virus (HCV) infection has been identified
s the major cause of posttransfusional and community-
cquired non-A, non-B hepatitis (Choo et al., 1989; Kuo et
l., 1989; Alter et al., 1992). More than half of the infec-
ions become chronic, and a high number of patients has
ssociated cirrhosis and hepatocellular carcinoma (Saito
t al., 1990). Diagnostic procedures have been estab-
ished following the molecular cloning and expression of
he HCV genome (Choo et al., 1989; Kuo et al., 1989;
rown et al., 1992). Prevention of HCV infection, however,
emains an urgent challenge due to the high mutation
ate of HCV.
Hypervariable region 1 (HVR1), which is located in the
mino-terminus of E2 of HCV, may contain epitopes for
eutralizing antibodies (Weiner et al., 1992; Kato et al.,
993; Taniguchi et al., 1993; Kojima et al., 1994). Antibod-
es to HVR1 in human sera have been shown to block
iral attachment (Shimizu et al., 1994; Zibert et al., 1995)
nd to protect chimpanzees from HCV infection (Farci et
l., 1994). Animal antibodies raised to this region have
revented viral infection in cell cultures (Shimizu et al.,
The GenBank/EMBL/DDBJ Accession Nos. of the sequences re-
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360996) and have provided effective prophylaxis in chim-
anzee challenge experiments (Farci et al., 1996; M.
sumi et al., 1999). HCV isolates, however, show mark-
dly different sequences in HVR1 among patients, and
here are often multiple closely related variants or qua-
ispecies in an individual during the course of the infec-
ion (Weiner et al., 1992; Martell et al., 1992; Kato et al.,
994; van Doorn et al., 1995). The high HVR1 mutation
ate is hypothesized to be caused by immune selection,
hich may generate escape mutants and lead to persis-
ent infection even after development of antibodies
gainst HVR1 in the sera of patients (Weiner et al., 1992;
ato et al., 1993; Taniguchi et al., 1993). Hence, it remains
oubtful whether HVR1 may be used to develop a pro-
hylactic vaccine because of this high HVR1 sequence
eterogeneity among diverse virus isolates. The devel-
pment of an effective and readily applicable vaccine for
CV infection may therefore require a broadening of the
eactivity of anti-HVR1 antibodies.
We recently demonstrated that HCV can be captured
y murine anti-HVR1 antibodies against different HCV
solates in vitro and that the HVR1 sequence from the
aptured HCV is cross-reactive with anti-HVR1 antibod-
es in ELISA (Esumi et al., 1998). To investigate the
pplicability of an anti-HVR1 antibody response in the
evelopment of a broadly reactive pattern, we examined
he cross-reactivity of anti-HVR1 antibody response not
nly in HCV-infected patients but also in experimental
nimal models immunized with synthetic HVR1 peptides.
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361INDUCIBILITY OF CROSS-REACTIVE ANTI-HCV HVR1 Absurthermore, we tried to determine the basis of this
ross-reactivity by fine epitope mapping of chimpanzee
nti-HVR1 antibodies and mouse monoclonal antibodies
mAbs) cross-reactive to different HVR1 sequences.
RESULTS
eactivity of anti-HVR1-#7 antibodies to HVR1-#6-1
eptide
We recently found that murine anti-HVR1 antibodies
gainst HCV-#6 were able to capture a different HCV
solate, i.e., HCV-#7, in vitro and that the antibodies were
ross-reactive to HVR1-#7 (Esumi et al., 1998). Chimpan-
ee antiserum obtained by hyperimmunization with
VR1-#6 peptides was also reactive to HVR1-#7 (data
ot shown). The amino acid sequences of these two
VR1 are shown in Fig. 1a. To further characterize this
ross-reactivity, we examined mutual reactivity, that is,
nti-HVR1-#7 antibody cross-reactivity to HVR1-#6-1
eptide. We obtained anti-HVR1-#7 antibodies by immu-
izing mice and a chimpanzee with synthetic HVR1-#7
eptide. The humoral immune response to these pep-
ides was similar in six mice, three each of the BDF1 and
57BL/6J strains (data not shown). The antibodies
gainst HVR1-#7 in all three BDF1 mice and two out of
hree C57BL/6J mice were reactive with HVR1-#6-1 pep-
ide. Figure 1b shows the representative titration of anti-
VR1-#7 antibodies to HVR1-#6-1 peptide from a BDF1
ouse. Similarly, as shown in Fig. 1b, antibodies against
VR1-#7 produced in the chimpanzee were also reactive
o HVR1-#6-1. Therefore anti-HVR1-#7 antibodies in-
uced in mice and a chimpanzee had the capacity to
ecognize a different HVR1 sequence, HVR1-#6-1. Taken
ogether with the finding of anti-HVR1-#6 antibodies re-
ctive to the HVR1-#7 sequence (Esumi et al., 1998), the
FIG. 1. Alignment of amino acid sequences of HVR1 and synthetic pe
s represented by dashes. Synthetic peptides of various lengths are sh
ne of the immunized BDF1 mice and chimpanzee 260. E and F, mo
himpanzee antibodies reactive to HVR1-#7 and HVR1-#6-1, respectiventibodies against HVR1-#6 and HVR1-#7 sequences are presumably mutually cross-reactive to each of these
wo HVR1 sequences.
VR1 sequences in HCV-infected patients sera
ositive for anti-HVR1-#6-1 and/or HVR1-#7
ntibodies
To examine whether animal antisera against HVR1-
6-1 and HVR1-#7 react with other HCV HVR1 se-
uences, we first identified these HCV HVR1 candidates
y screening HCV-infected individuals who were positive
or anti-HVR1-#6-1 and/or anti-HVR1-#7 antibodies. The
VR1 sequences in these individuals were presumed to
e regions potentially reactive to the two anti-HVR1 an-
ibodies. This was based on the observation that most
CV-infected patients develop antibodies against HVR1
Weiner et al., 1992; Kato et al., 1993; Kojima et al., 1994).
able 1 shows the anti-HVR1 antibody positive rates in a
otal of 165 HCV-infected individuals. As previously re-
orted (Scarselli et al., 1995; Jackson et al., 1997), multi-
a) and reactivity of anti-HVR1-#7 antibodies (b). (a) Amino acid identity
elow the sequences. (b) Anti-HVR1-#7 antibodies were obtained from
tibodies reactive to HVR1-#7 and HVR1-#6-1, respectively;  and ,
TABLE 1
Antibody Responses Directed to HVR1-#6-1 and HVR1-#7 Peptides
in 165 HCV-Infected Individuals
Ab to HVR1-#6-1
Total1 2
b to HVR1-#7
1 8 18 26 (15.8)
2 3 136 139
otal 11 (6.7) 154 165
Note. The antibody response was tested by peptide ELISA. Values of
bsorbance at 450 nm more than 0.25 were considered positive. Pos-
tive rates of respective anti-HVR1 antibodies are shown as percent-ptides (
own b
use anges in parentheses.
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362 ZHOU, MORIYAMA, AND ESUMIle HCV-infected patient sera were reactive to an unre-
ated patient’s HCV HVR1 sequence. Of the 29 patients
ositive for either of these two anti-HVR1 antibodies, 27
ere positive for HCV RNA with three genotypes, 1b, 2a,
nd 2b. Interestingly, eight samples were simultaneously
ositive for antibodies to both #6-1 and #7 sequences.
We selected six samples strongly reactive to HVR1-
6-1 and/or HVR1-#7 peptides, S1422, S6669, P33,
3636, S1, and S8350. The first three sera were positive
or both antibodies, whereas the last three were positive
nly for anti-HVR1-#7 antibodies. We determined the
VR1 sequences in these six patients. The HVR1 se-
uence from another serum sample, P32, which showed
o reactivity to either HVR1-#6-1 or HVR1-#7, was ana-
yzed as a negative control. The deduced amino acid
FIG. 2. Alignment of deduced amino acid sequences of HVR1 (amino
ucleotide sequences (b). (a) Six patients, S1422–S8350, were positiv
egative for both anti-HVR1-#6-1 and anti-HVR1-#7, served as a negati
n P33, S3636 and S1. (b) NT-1–NT-5 were reference related HVR1 sequ
f patient P32. Bootstrap analysis was performed 1000 times and theequences of HVR1 in these six individuals are shown in slignment in Fig. 2a. Because all six patients were pos-
tive for anti-HVR1-#7, these HVR1 sequences were com-
ared with that of HVR1-#7. There were at least two
ajor sequences in each of the three patients, S3636, S1,
nd P33, based on the subclones analyzed. The amino
cid sequences of HVR1 in these individuals and the
equences of HVR1-#6-1 and #7 differed substantially.
he identity of these HVR1 sequences was only 50–
4.5%.
To determine the evolutionary relationship between
hese HVR1 sequences, a 101-bp fragment from the be-
inning of E2 region covering the HVR1 sequence was
sed to construct a phylogenetic tree (Fig. 2b). NT-1–
T-5 constituted 101-bp sequences of HVR1 at five con-
ecutive time points from an HCV-infected patient (Kuro-
84-414) from HCV-infected individuals (a) and phylogenetic tree of the
ntibodies against HVR1-#6-1 and/or HVR1-#7 peptides. Patient P32,
rol. The subclone analysis shown on the right indicates quasispecies
The scale shows the genetic distance. NC, negative control sequence
are shown at each branch.acid 3
e for a
ve cont
ences.
valuesaki et al., 1994) and were used as a reference group.
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363INDUCIBILITY OF CROSS-REACTIVE ANTI-HCV HVR1 Abshe reference sequences, NT-1–NT-5, were closely re-
ated, whereas other HVR1 clones were not closely re-
ated to each other, most notably not to either #6-1 or #7.
ootstrap values also confirmed the unrelatedness of
hese sequences except for quasispecies of HCV within
he individual patients, P33, S1, and S3636.
ntibody responses to HVR1 sequences of HCV-
nfected patients and immunized animals
To determine whether the HCV-infected individual sera
elected by the presence of an antibody response to
VR1-#6-1 and/or HVR1-#7 were also reactive to each
ther’s HVR1 sequences, each respective synthetic pep-
ide of these nine HVR1 sequences (Fig. 2a) was tested
or the reactivity to each serum of these patients by
LISA. P32 served as a negative control peptide. All
ositive reactivity between HVR1 peptides and patient
era was confirmed by .50% inhibition on the inhibition
est (data not shown). Figure 3a shows that HVR1 pep-
ides of S1422, S3636-1, S3636-2, S1-1, S1-2, and S8350
eacted with antibodies in four to all of these six patients,
nd peptide P33-2 weakly reacted with one patient se-
um S1.
Sera from HCV-infected individuals contain all antibod-
es generated in response to the antigenic drift of HCV or
FIG. 3. Reactivity of anti-HVR1 antibodies to multiple sequences. The
s absorbance at 450 nm on the abscissa. Coated HVR1 peptides are
ntibody responses to various HVR1 peptides in HCV-infected individu
bsorbance at 450 nm .0.25 were considered positive. (b) Reactiv
nti-HVR1-#7 antisera were collected from chimpanzees and mice imm
ice, 500- and 50-fold diluted, respectively, are shown on the left. Valu
ontrol chimpanzee serum. NMS, negative control mouse serum.ultiple infection, that is, not only from the response to phe present HCV infection but also from that to past
nfection. It is difficult to accurately determine whether
ifferent antibodies to different HVR1 or cross-reactive
ntibodies react to the unrelated HVR1 sequences. We
xamined the cross-reactivity of animal antisera against
VR1-#6-1 and HVR1-#7 to the respective synthetic pep-
ides. Figure 3b shows that, of a total of nine HVR1
eptides, eight reacted with both chimpanzee anti-HVR1
ntibodies against HVR1-#6-1 and HVR1-#7. Similarly,
even and six HVR1 peptides were capable of reacting
ith mouse antibodies against HVR1-#6-1 and HVR1-#7,
espectively. Only one peptide, S1422, did not react with
nti-HVR1 antibodies produced by either the chimpan-
ees or mice, but this peptide reacted with the sera from
ive HCV-infected individuals including patient S1422
Fig. 3a). On the other hand, the S6669 and P33-1 pep-
ides showed no reactivity in HCV-infected individuals
Fig. 3a) but reacted with chimpanzee anti-HVR1 antibod-
es and/or mouse anti-HVR1 antibodies (Fig. 3b). The
egative control sera showed no reactivity to any peptide
f these HVR1 sequences.
nhibition of cross-reactivity with HVR1 peptides
To determine whether or not antibodies cross-reactive
ith various HVR1 sequences are the same species, we
vity of antibodies to each HVR1 was determined by ELISA, and shown
above the figure. The results are the averages of two experiments. (a)
e corresponding sera, 50-fold diluted, are shown on the left. Values of
nimal antibodies to multiple HVR1 sequences. Anti-HVR1-#6-1 and
by corresponding HVR1 peptides. The antisera from chimpanzees and
bsorbance at 450 nm .0.22 were considered positive. NCS, negativereacti
shown
als. Th
ity of a
unized
es of aerformed cross-inhibition tests with various HVR1 pep-
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364 ZHOU, MORIYAMA, AND ESUMIides in each ELISA of chimpanzee antisera. Figure 4
hows one-to-one cross-reaction of 10 HVR1 peptides,
hich were cross-reactive to anti-HVR1-#6 and anti-
VR1-#7 antibodies. In most peptides, the cross-reaction
as mutually inhibited by various soluble competing
eptides except for negative control peptide P32. The
eactivity of anti-HVR1-#6 to peptide S6669 was partially
nhibited by several HVR1 peptides, but peptide S6669
nhibited all peptide reactions (Fig. 4a). Similarly, the
eactivity of anti-HVR1-#7 antibodies to S6669 or P33-1
as also partially inhibited by most peptides, whereas
eptide P33-1 completely inhibited all peptide reactions,
s did peptide S6669 except in the case of P33-1 (Fig.
b). Our findings suggest that these chimpanzee antisera
ssentially contain a given species of the antibody cross-
FIG. 4. Dose-dependent cross-inhibition of binding of anti-HVR1 a
nti-HVR1-#6 (a) and anti-HVR1-#7 (b) antibodies were diluted adequa
re coated HVR1 peptides. Soluble competing peptides are shown on t
inding measured under the same conditions except that only PBS seeactive to multiple HVR1 sequences. tine epitope mapping of cross-reacting antibodies
To determine the molecular basis of the immunologi-
al cross-reactivity to HVR1, epitope mapping was per-
ormed using these two mutually cross-reacting antibod-
es, anti-HVR1-#6 and -#7 antibodies, and a serial of
ynthetic peptides as shown in Fig. 1a. We first identified
hat the cross-reacting epitopes were located within
mino acid 395-414 region. Figure 5a shows that anti-
VR1-#6 antibodies were reactive to peptides 1-31 and
2-31 but not to peptide 1-20 of HVR1-#7 and that anti-
VR1-#7 antibodies were reactive to peptides 1-31 and
2-31 but not to peptide 1-20 of HVR1-#6-1. It is notable
hat neither anti-HVR1-#6 nor anti-HVR1-#7 reacted to
eptide 11-30, but both antibodies cross-reacted to pep-
es to solid-phase peptides by soluble HVR1 peptides. Chimpanzee
d applied in an ELISA inhibition assay. Designations above the figure
t. Binding activity is expressed as a percentage of anti-HVR1 antibody
a competitor.ntibodi
tely an
he righ
rved aside 12-31. This suggests that the single amino acid at the
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365INDUCIBILITY OF CROSS-REACTIVE ANTI-HCV HVR1 Absterminus in this study is essential for the cross-reac-
ivity. We then performed cross-inhibition ELISA using
arious length peptides as competing antigens to define
he shortest sequence for the cross-reactivity. Because
he cross-reacting epitopes were located within amino
cid 395-414 as shown above, ELISA plates were coated
y corresponding peptide 12-31. Figure 5b shows that the
eactivity of anti-HVR1-#6 antibodies was significantly
nhibited by peptides 12-31, 21-31, 22-31, and 24-31 de-
ived from HVR1-#7. Similarly, peptides from same re-
ions derived from HVR1-#6-1 significantly inhibited the
eactivity of anti-HVR1-#7 antibodies (Fig. 5c). Peptide
6-31 showed no significant inhibition. Interestingly, the
ross-inhibition also was abolished by a single amino
cid deletion from the C terminus (Figs. 5b and c). There-
ore the region of amino acid 407-414 in both HVR1-#6-1
nd HVR1-#7 was considered the cross-reactive epitope
f chimpanzee antibodies. A sequence comparison of
his region in HVR1-#6-1 and HVR1-#7 (Fig. 1a) suggests
hat a conserved sequence in the C-terminal region of
VR1 gives rise to the cross-reactivity.
To further clarify whether the conserved sequence is
esponsible for the cross-reactivity to other HVR1 se-
uences as demonstrated in Fig. 3b, we tested the re-
FIG. 5. Cross-binding reactivity (a) and cross-binding inhibition (
nti-HVR1-#7 (h) antisera diluted 500-fold were added to ELISA plate
equences of coated peptides are shown in Fig. 1a. (b and c) Chimp
espectively preincubated with competing peptides of various lengths de
eparately coated by peptides #7(12-31) (b) and #6-1(12-31) (c). Result
xperiment except that competing peptides were replaced by PBS.idual reactivity of anti-HVR1-#6 and anti-HVR1-#7 to nther HVR1 sequences after the antibodies were prein-
ubated with corresponding peptides 21-31 and 24-31.
he findings show that the cross-reactivity to other eight
VR1 sequences was significantly inhibited by both pep-
ides 21-31 and 24-31. Figure 6 shows the representative
esults that the cross-reactivity to one of the other HVR1
equences (S8350) was inhibited by peptides 21-31 and
4-31, respectively. The negative control peptide 1-20
howed no inhibition. The sequence at aa 24-31 of HVR1-
8350 is PAQKIQLV, of which six and five residues are
dentical to those of HVR1-#6 and HVR1-#7, respectively.
hese data indicate that the conserved sequence in the
-terminal region is indeed responsible for the cross-
eactivity.
onoclonal antibodies with cross-reactivity
To elucidate the mechanism of the cross-reactivity of
VR1 sequences furthermore, we developed two mAbs,
ach specific to HVR1-#6-1 and HVR1-#7, and examined
heir reactivity to other HVR1 sequences. The mAb
gainst HVR1-#6-1, designated 30F3, was directed to
mino acid 394-403 region, and the mAb against HVR1-
7, designated 5A9, to amino acid 384-393 region (data
c) of anti-HVR1 antibodies. (a) Chimpanzee anti-HVR1-#6 (1) and
oated by various peptides indicated on the abscissa. The amino acid
ntisera against HVR1-#6 (b) and HVR1-#7 (c) diluted 2000-fold were
rom HVR1-#7 (b) and HVR1-#6-1 (c) and then added to the ELISA plates
xpressed as a percentage of antibody binding measured in the sameb and
wells c
anzee a
rived f
s are eot shown). Figure 7 shows that both mAbs were cross-
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366 ZHOU, MORIYAMA, AND ESUMIeactive to another HVR1 sequence, respectively, among
even reactive peptides shown in Fig. 3b. mAb 30F3 was
ross-reactive to HVR1-S1-1 (Fig. 7a), and mAb 5A9 was
ross-reactive to HVR1-P33-1 (Fig. 7b). Neither of these
wo mAbs showed reactivity to other HVR1 sequences
data not shown). The epitope of each mAb for the cross-
eactivity was determined by inhibition ELISA. The bind-
ng reactivity of mAb 30F3 to HVR1-#6-1 was inhibited by
ot only peptide #6-1(11-20) but also peptide S1-1(11-20)
Fig. 7c). Similarly, peptide 1-10 derived from both #7 and
33-1 inhibited the reactivity of mAb 5A9 to HVR1-#7 (Fig.
d). The other 10-amino acid peptides in Fig. 1a showed
o inhibition (data not shown). Amino acid comparison
hows that 8 of 10 residues in amino acid 394-403 of
6-1 and S1-1 are identical (Fig. 7c) and that 7 of 10 in
mino acid 384-393 of #7 are consistent with those of
33-1 (Fig. 7d). These data provide the further evidence
hat conserved subregions of HVR1 sequences indeed
lay an important role in the cross-reactivity.
DISCUSSION
We herein directly demonstrated by experimental im-
unization that immunological epitopes in HVR1 of HCV
ere reactive not only to the homologous HCV isolate
ut also to different HCV isolates. Such immunological
ross-reactivity could be interpreted by the conserved
ubregions in different HVR1 sequences.
Scarselli et al., (1995) and Jackson et al., (1997) previ-
usly showed that anti-HVR1 antibodies in HCV-infected
ndividuals could react with more than one variant of
VR1, as we also demonstrated in our present study. A
ingle infected patient, however, had multiple quasispe-
FIG. 6. Inhibition of binding of anti-HVR1 antisera to solid phase HV
nti-HVR1-#7 (b) diluted adequately were preincubated with correspond
lates coated by HVR1-S8350 peptide. The aa sequence of HVR1-S835
op. Results are represented as a percentage of antibody binding measuies that could change progressively either by continu- pus mutation or by selective over-expression of a partic-
lar single variant (Weiner et al., 1992; Kato et al., 1993;
urosaki et al., 1994). A wide range of anti-HVR1 anti-
odies might therefore be produced and accumulate in a
atient over time, resulting in a broadening of the reac-
ivity of anti-HVR1 antibodies. To exactly determine the
mmunological cross-reactivity of HVR1, we immunized
xperimental animals, chimpanzees and mice, for cross-
eactive assessment (Fig. 3b). There were no accumu-
ated antibodies against different HVR1 sequences in the
era of these experimental animals, but the anti-HVR1
ntibodies reacted with multiple HVR1 sequences.
ence, our data provide direct evidence that HVR1 se-
uences can induce anti-HVR1 antibodies capable of
eacting with many HVR1 sequences in vitro other than
he original challenge sequence. This is in agreement
ith a recent observation on the cross-reacting mimo-
opes of HVR1 (Puntoriero et al., 1998). Additionally, the
nti-HVR1 antibodies induced in the chimpanzees rec-
gnized more diverse sequences than those induced in
ice (Fig. 3b). This probably means that the immune
esponse to immunized HVR1 peptides in primates is
ore evolved than that in nonprimates.
The mechanism of HVR1 sequence cross-reactivity is
ot yet known. The cross-inhibition assay (Fig. 4) sug-
ests that, at a minimum, a given antibody species re-
ctive to the multiple HVR1 peptides is induced in im-
unized chimpanzees. The HVR1 sequences in our pa-
ients were remarkably divergent except several amino
cids at the C termini (Fig. 2a). These relatively con-
erved C termini probably play roles in the cross-reac-
ivity of anti-HVR1 antibodies. Actually, the epitope map-
50 by soluble competing peptides. Chimpanzee anti-HVR1-#6 (a) and
1 peptides. The residual reactivity of the antisera was tested on ELISA
mpared with those of HVR1-#6-1 (a) and HVR1-#7 (b) indicated at the
der same conditions where competing peptides were replaced by PBS.R1-S83
ing HVR
0 is coing of cross-reacting antibodies (Fig. 5) and the cross-
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367INDUCIBILITY OF CROSS-REACTIVE ANTI-HCV HVR1 Absnhibition test to other HVR1 sequences (Fig. 6)
emonstrate that antibody species against the C-termi-
al conserved sequences at amino acid 407-414 of HVR1
s responsible for the cross-reactivity to multiple HVR1
equences. A recent report on the fine mapping of HVR1
sing HCV-infected patient sera also suggests that the
eactivity of isolate-independent anti-HVR1 antibodies is
elated partly to the C terminus of HVR1 (Zibert et al.,
997). Furthermore, fine mapping of the cross-reacting
Abs prepared from the mice immunized with HVR1-
6-1 or HVR1-#7 reveals that mostly identical amino acid
equences are responsible for the cross-reactivity (Figs.
c and d). Therefore the cross-reactivity of the HVR1
equences is mediated at least partially by the con-
erved fragments in HVR1.
Of interest is the observation that the cross-reactivity
f antibodies against HVR1-#6 and HVR1-#7 was abol-
FIG. 7. Binding reactivity (a and b) and cross-inhibition of binding (c a
oated by HVR1 peptides shown on the upper right. (a) mAb 30F3, aga
A9 (d) were preincubated with different doses of soluble competing
VR1-#6-1 (c) and HVR1-#7 (d). The HVR1 sequences from which comp
esidues.shed completely after deletion of a single amino acid at ahe C terminus (Fig. 5a). Similarly, such a deletion also
esulted in a complete loss of cross-reactivity as a cross-
ompeting peptide (Figs. 5c and d). Indeed, we found
hat even a substitution of the residue at 414 blocked the
ignificant inhibition (data not shown). This suggests that
he residue at the C terminus of the peptide is an essen-
ial determinant for the cross-reactivity in this work. The
echanism responsible for this phenomenon remains
nclear. It is likely to be related to the fact that immuni-
ation with the C-linked peptide results in antibodies
eactive with a site in the peptide near the C-terminus
Dyrberg and Oldstone, 1986).
HVR1 has the potential to provide a viral antigen for
accine development, and the cross-reactivity of HVR1
equences is an essential consideration in the develop-
ent of a broadly reactive vaccine to prevent HCV infec-
ion. We found that anti-HVR1 antibodies elicited by even
f mAbs. (a and b) The binding reactivity was examined on ELISA plates
R1-#6-1; (b) mAb 5A9, against HVR1-#7. (c and d) mAbs 30F3 (c) and
des shown on the right and then added to ELISA plates coated by
eptides were derived are shown at the top. Dashes represent identicalnd d) o
inst HV
pepti
eting psingle peptide immunization in mice and chimpanzees
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368 ZHOU, MORIYAMA, AND ESUMIecognized many other HVR1 sequences in vitro. Our
esults highlight the applicability of HVR1 in the devel-
pment of a broadly reactive antibody response. We
ompared 163 unrelated (exclusion of quacispecies)
VR1 sequences corresponding to amino acid 407-414
rom the HCV database (National Institute of Genetics
nd Second Department of Medicine, Nagoya City Uni-
ersity Medical School, Japan). The frequency of the
mino acid identical to our cross-reacting epitope of
himpanzee antibodies was 20.2% (data not shown). It
ndicates that antibodies induced by a single HVR1 pep-
ide immunization can react with 20% of HVR1 variants.
ecently, a new strategy that can induce cross-reactive
ntibodies has also been developed by using mimotopes
f HVR1 (Puntoriero et al., 1998). However, it remains
ecessary to confirm whether the cross-reactivity of
VR1 sequences in vitro means cross-protection against
CV challenge in vivo. If so, it may eventually be possible
o develop a polyvalent vaccine using a mixture of sev-
ral HVR1 sequences that cover the reactivity of most
CV isolates.
MATERIALS AND METHODS
uman sera
Samples of HCV-infected sera were obtained from a
anel of 56 blood donors who were positive for HCV
NA. Another 109 serum samples were taken from
hronic HCV-infected patients. HCV infection was con-
irmed by the presence of anti-HCV antibodies and/or
CV RNA. The genotypes of HCV were determined as
escribed previously (Okamoto et al., 1992). The sera
ere aliquoted and stored at 280°C.
everse transcription and PCR
Total RNA was extracted from 100 ml of serum after the
ddition of 1 ml of TRIzol Reagent (Life Technologies,
aithersburg, MD) according to the manufacturer’s pro-
ocol. The extracted RNA was reversely transcribed into
DNA using 100 U Moloney murine leukemia virus re-
erse transcriptase (Life Technologies) and 100 pmol
exa random primer (Takara, Kyoto, Japan) in 20 ml of
ixture. Half of the cDNA was subjected to nested poly-
erase chain reaction (PCR) by using 0.5 U Taq-DNA
olymerase (Life Technologies) and 15 pmol of primers
n a volume of 50 ml. One-tenth of the first PCR products
as used in the second round of PCR. The outer primers
ere 59-GCGGGCCTTGCCTACTATTC-39 (nt 1410–1429)
nd 59-GGGCACCCGGACGAGTTGAA-39 (nt 1699–1680);
nd the inner primers, 59-CATGGCGGGGAACTGGGCTA-
GGT-39 (nt 1430–1453) and 59-CAGGGCAGTCCTGTT-
ATGTGCCA-39 (nt 1622–1599). The two rounds of PCR
ere both run with 35 cycles of 30 s at 94°C, 45 s at
5°C, and 1 min at 72°C, followed by extension for 10
in at 72°C. iVR1 sequence analysis
Amplified PCR products of HVR1 were purified with a
icrocon 100 (Amicon, Beverly, MA) and directly se-
uenced using a dye primer cycle sequencing ready
eaction kit (Perkin-Elmer Applied Biosystems, Foster
ity, CA) on a 310 automated DNA sequencer (Perkin-
lmer Applied Biosystems) according to the manufactur-
r’s protocol. To detect HVR1 sequence variants in each
ample, the purified PCR products were cloned into
-tailed pGEM4Z vectors by a T–A overhang cloning
ethod (Marchuk et al., 1991). The plasmids were trans-
ormed into Escherichia coli JM109 competent cells
Toyobo, Osaka, Japan). At least five independent clones
ere analyzed for each sample with same primers as
eported before (Esumi et al., 1998). The nucleotide se-
uences were translated by the DNASIS program ver-
ion 3.6 (Hitachi Software Engineering, Yokohama, Ja-
an). Phylogenetic analysis of 101-bp sequences cover-
ng the HVR1 was carried out with the neighbor-joining
ethod (Saitou and Nei, 1987) using Clustal W 1.5 com-
uter software (Thompson et al., 1994).
eptide synthesis
The peptides were synthesized in an automated mul-
ipeptide synthesizer (PSSM-8, Shimadzu, Japan) accord-
ng to the manufacturer’s instructions. After being
leaved and lyophilized, each peptide was analyzed by
eversed-phase high-performance liquid chromatogra-
hy (HPLC) to check peptide purity. If two or more main
PLC peaks appeared, the peptides were subsequently
urified by reverse HPLC with a SynProPep column (type
PC 18, 20 3 150 mm, Shimadzu). The authenticity of
xpected peptides was confirmed by amino acid se-
uence analysis using a PSQ10 amino acid sequencer
Shimadzu). The peptides used in the immunization of
nimals were coupled with an equal amount of maleim-
de-activated keyhole limpet hemocyanin (KLH) (PIERCE,
ockford, IL) by adding a cysteine at the C-terminus to
onfer an immune response to peptides in the animals.
nimal antisera
Immunogens and immunization procedures were ba-
ically the same as described previously (Esumi et al.,
998). HVR1-#6-1 and HVR1-#7 sequences, derived from
CV-#6 and HCV-#7, respectively, are shown in Fig. 1a.
hree mice, which were of two different strains, BDF1
nd C57BL/6J, were injected intraperitoneally and sepa-
ately with 50 mg of HVR1-#6-1 and HVR1-#7 peptides
onjugated with KLH, which were emulsified in an equal
olume of complete Freunds adjuvant (CFA) (DIFCO, De-
roit, MI), as the primary immunization for each of the
ice. Next, three booster immunizations were carried
ut weekly in the same way except that the adjuvant wasncomplete Freunds adjuvant (IFCA) (DIFCO). Five days
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369INDUCIBILITY OF CROSS-REACTIVE ANTI-HCV HVR1 Absfter the fourth booster immunization and 1 month after
he third booster, antisera were collected (by sacrificing
he mice) and aliquoted and stored at 220°C. The sera
rom mice that were immunized with KLH only, using the
ame method, served as a negative control.
Chimpanzee 260 was immunized subcutaneously us-
ng 200 mg of HVR1-#7 peptide coupled with KLH, at
ntervals of 4 weeks, which had first been emulsified with
FA and then with IFCA. The antiserum was collected 1
eek after the fourth booster immunization. Anti-
VR1-#6 serum was obtained from chimpanzee 228 dur-
ng a vaccination study of synthetic HVR1 peptides, #6-1,
6-2, and #6-3, quasispecies of HCV-#6 (Esumi et al.,
999). The animal was immunized with 500 mg each of
ynthetic peptides four times. The antiserum was col-
ected 1 week after the final booster immunization.
onoclonal antibodies
Three 8-week-old mice BDF1 were immunized intra-
eritoneally by HVR1-#6-1 and -#7 peptides, respectively,
s above. Spleen cells obtained 5 days after the last
ooster immunization were fused with myeloma cells
3-X63-Ag8-U1 (P3U1) from the BALB/c strain using poly-
thylene glycol 1500. Hybridoma cells were cloned by a
imited dilution method in the presence of 104 peritoneal
acrophages per well and were screened against both
VR1-#6-1 and HVR1-#7 peptides. Ascitic fluid was pre-
ared in BALB/c mice, and the mAbs, 30F3 against
VR1-#6-1 and 5A9 against HVR1-#7, were purified by
he Protein A-affinity column chromatography. These
Abs were isotyped by ELISA, both as IgG2b k.
LISA and inhibition test
ELISA was performed on 96-well microtiter plates
Nunc, Roskilde, Denmark) as previously described
Ahmed et al., 1996). Serum samples were variously
iluted with PBS containing 5% skim milk and 0.05%
ween 20, and 100-ml portions were added to the plate to
etermine the reactivity to the coated antigens. The neg-
tive control human sera were derived from 10 blood
onors who were all negative for anti-HCV antibodies
nd HCV RNA, and had ALT levels ,20 IU/L. The nega-
ive controls of chimpanzee sera and mouse sera were
btained from preimmunized chimpanzees and KLH-im-
unized mice, respectively. The cutoff was established
s twice the average 1 3 SD of negative control sam-
les.
The inhibition ELISA test was performed to confirm the
pecificity of the positive binding reaction, to determine
hether the same antibody species reactive to different
VR1 sequences, and to identify epitopes of cross-reac-
ive anti-HVR1 antibodies. Adequately diluted antisera or
Abs were preincubated with various amounts of solu-
le competing HVR1 peptides in PBS (pH 7.4) for 1 h at
7°C. Mixtures then were transferred into ELISA wellsrecoated with each of the corresponding HVR1 pep-
ides. Subsequent steps were the same as those of
LISA. The remaining binding reactivity of anti-HVR1
ntibodies was expressed as the percentage of their
inding reactivity measured under identical conditions
xcept that the soluble competing HVR1 peptides were
eplaced by PBS.
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